NASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free ITOS Stock Alerts $13.17 +0.82 (+6.64%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$12.56▼$13.4250-Day Range$9.89▼$13.1752-Week Range$8.20▼$18.24Volume595,613 shsAverage Volume249,602 shsMarket Capitalization$472.01 millionP/E RatioN/ADividend YieldN/APrice Target$30.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get iTeos Therapeutics alerts: Email Address iTeos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside130.3% Upside$30.33 Price TargetShort InterestBearish7.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.76) to ($6.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.86 out of 5 starsMedical Sector623rd out of 939 stocksBiological Products, Except Diagnostic Industry105th out of 156 stocks 3.5 Analyst's Opinion Consensus RatingiTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.33, iTeos Therapeutics has a forecasted upside of 130.3% from its current price of $13.17.Amount of Analyst CoverageiTeos Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.05% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 11.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ITOS. Previous Next 2.3 News and Social Media Coverage News SentimentiTeos Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for iTeos Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 19 people have searched for ITOS on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows6 people have added iTeos Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.20% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($4.76) to ($6.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About iTeos Therapeutics Stock (NASDAQ:ITOS)Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.Read More ITOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITOS Stock News HeadlinesMarch 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: iTeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)March 20, 2024 | americanbankingnews.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest UpdateMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 11, 2024 | finance.yahoo.comITOS Oct 2024 17.000 callMarch 11, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)March 10, 2024 | finance.yahoo.comITOS Oct 2024 12.000 callMarch 10, 2024 | finance.yahoo.comITOS Mar 2024 4.000 putMarch 6, 2024 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 6, 2024 | finance.yahoo.comITOS Mar 2024 11.000 callMarch 6, 2024 | globenewswire.comiTeos Appoints Oncology Veteran Jill DeSimone to Its Board of DirectorsMarch 6, 2024 | globenewswire.comiTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 5, 2024 | globenewswire.comiTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024March 1, 2024 | globenewswire.comiTeos to Participate in Upcoming Investor ConferencesJanuary 3, 2024 | finance.yahoo.comiTeos to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 13, 2023 | finance.yahoo.comWall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to TradeNovember 29, 2023 | fool.comiTeos Therapeutics (NASDAQ: ITOS)November 27, 2023 | finance.yahoo.comDoes iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?November 21, 2023 | finance.yahoo.comiTeos to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comiTeos Therapeutics’ Anticipated Growth and Clinical Updates Drive Buy Rating: An Analyst’s PerspectiveNovember 13, 2023 | finance.yahoo.comHere's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom FisherNovember 10, 2023 | finance.yahoo.comWall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should KnowNovember 10, 2023 | finance.yahoo.comWall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should KnowNovember 9, 2023 | markets.businessinsider.comPositive Financial Results and Promising Cancer Treatment Programs Underpin Buy Rating for iTeos TherapeuticsNovember 7, 2023 | finance.yahoo.comiTeos Reports Third Quarter 2023 Financial Results and Provides Business UpdatesOctober 31, 2023 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?October 19, 2023 | msn.comWedbush Reiterates ITeos Therapeutics (ITOS) Outperform RecommendationSee More Headlines Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ITOS CUSIPN/A CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees157Year FoundedN/APrice Target and Rating Average Stock Price Target$30.33 High Stock Price Target$44.00 Low Stock Price Target$18.00 Potential Upside/Downside+130.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,640,000.00 Net MarginsN/A Pretax Margin-865.66% Return on Equity-18.40% Return on Assets-16.22% Debt Debt-to-Equity RatioN/A Current Ratio13.76 Quick Ratio13.76 Sales & Book Value Annual Sales$12.60 million Price / Sales37.46 Cash FlowN/A Price / Cash FlowN/A Book Value$16.08 per share Price / Book0.82Miscellaneous Outstanding Shares35,840,000Free Float32,187,000Market Cap$472.01 million OptionableOptionable Beta1.15 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Michel Detheux Ph.D. (Age 57)President, CEO & Director Comp: $922.38kMr. Matthew A. Call M.B.A. (Age 51)Chief Operating Officer Comp: $638.55kMr. Matthew Gall (Age 46)Chief Financial Officer Comp: $628.45kDr. Yvonne McGrath Ph.D. (Age 50)Chief Scientific Officer Ms. Adi OsovskyVP & Head of LegalMr. Phillipe BrantegemVice-President of Human ResourcesDr. Joyson Joseph Karakunnel FACP (Age 53)M.D., M.Sc., Interim Chief Medical Officer More ExecutivesKey CompetitorsCaribou BiosciencesNASDAQ:CRBUMetagenomiNASDAQ:MGXJasper TherapeuticsNASDAQ:JSPRAdaptive BiotechnologiesNASDAQ:ADPTOcugenNASDAQ:OCGNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 322,817 shares on 3/11/2024Ownership: 4.160%Goldman Sachs Group Inc.Bought 132,856 shares on 3/1/2024Ownership: 2.074%American International Group Inc.Sold 1,361 shares on 2/28/2024Ownership: 0.034%Readystate Asset Management LPBought 36,100 shares on 2/20/2024Ownership: 0.396%Public Employees Retirement System of OhioBought 13,207 shares on 2/16/2024Ownership: 0.104%View All Insider TransactionsView All Institutional Transactions ITOS Stock Analysis - Frequently Asked Questions Should I buy or sell iTeos Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITOS shares. View ITOS analyst ratings or view top-rated stocks. What is iTeos Therapeutics' stock price target for 2024? 3 analysts have issued twelve-month price targets for iTeos Therapeutics' stock. Their ITOS share price targets range from $18.00 to $44.00. On average, they expect the company's stock price to reach $30.33 in the next year. This suggests a possible upside of 130.3% from the stock's current price. View analysts price targets for ITOS or view top-rated stocks among Wall Street analysts. How have ITOS shares performed in 2024? iTeos Therapeutics' stock was trading at $10.95 on January 1st, 2024. Since then, ITOS shares have increased by 20.3% and is now trading at $13.17. View the best growth stocks for 2024 here. Are investors shorting iTeos Therapeutics? iTeos Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,010,000 shares, an increase of 11.7% from the February 29th total of 1,800,000 shares. Based on an average daily volume of 256,400 shares, the short-interest ratio is presently 7.8 days. Approximately 7.1% of the shares of the stock are short sold. View iTeos Therapeutics' Short Interest. When is iTeos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ITOS earnings forecast. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.18. What ETFs hold iTeos Therapeutics' stock? ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA). When did iTeos Therapeutics IPO? iTeos Therapeutics (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? iTeos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.17%), Vanguard Group Inc. (4.16%), Dimensional Fund Advisors LP (2.16%), Goldman Sachs Group Inc. (2.07%), Goldman Sachs Group Inc. (2.07%) and Barclays PLC (0.87%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ITOS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.